| Name | Acarbose |
| Description | Acarbose (BAY g 5421) is a hypoglycemic agent that is an inhibitor of orally active alpha-glucosidase (IC50=11 nM). Acarbose enhances the hypoglycemic effect of sulfonylureas or insulin. |
| Cell Research | Cell viability is determined using the MTT assay. Cells are seeded in 24-well culture plates at a density of 2×104 cells/well, incubated for 48 h, treated with acarbose at varying concentrations (0.5, 1.0, 2.0, 3.0, and 5.0 μM) for 24 h; or pre-treated with TNF-α (20 ng/mL) for either 24 h or 48 h to evaluate the dose-dependent effects of acarbose on VSMC growth and viability, cultured with 0.5 mg/mL MTT at 37°C in a humidified atmosphere of 5% CO2 for another 4 h, and solubilized with isopropanol. The viable cell number varies directly with the concentration of formazan product measured spectrophotometrically at 563 nm. |
| In vitro | METHODS: A7r5 cells pretreated with TNF-α were treated with Acarbose (1, 2, and 3 μM) and the expression levels of target proteins were detected by Western Blot.
RESULTS: Acarbose decreased the expression of β-galactosidase and Ras and increased the expression of p-AMPK in a dose-dependent manner. [1] |
| In vivo | METHODS: To study the hypoglycemic effect of Acarbose, rats were treated with Acarbose (30, 60 mg/kg) by gavage once daily for 8 weeks.
RESULTS: Acarbose reduced fasting glucose and modulated glucose tolerance without weight loss in DM rats. Acarbose significantly inhibited serum IL6 and TNF-α in DM rats. [2]
METHODS: To study the effect of Acarbose on atherosclerosis, rabbits were fed Acarbose (2.5-5.0 mg/kg) for 25 weeks.
RESULTS: Acarbose significantly and dose-dependent reduced the intensity of IL-6, TNF-α and iNOS staining, and significantly increased the intensity of p-AMPK staining in the neointima. Acarbose significantly and dose-dependent reduced neointimal Ras and β-galactosidase expression in HCD-fed rabbits without weight loss. [1] |
| Storage | Keep away from direct sunlight | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 50.00 mg/mL (77.45 mM), Sonication is recommended.
H2O : 64.50 mg/mL (99.91 mM), Sonication is recommended.
|
| Keywords | α-glucosidase | oral | mellitus | insulin | Inhibitor | inhibit | Glucosidase | BAY g-5421 | BAY g5421 | antihyperglycemic | anti-diabetes | Acarbose |
| Inhibitors Related | Cedryl acetate | X-GAL | Hexylresorcinol | Conduritol B epoxide | Gcase activator 2 | Fucoidan | Miglitol | Ambroxol hydrochloride | D-(-)-Quinic acid | (E)-3-(4-Methoxyphenyl)acrylic acid | Naringinase | 3-Butylidenephthalide |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Bioactive Compound Library | Pediatric Drug Library | Toxic Compound Library | Anti-Obesity Compound Library | Drug Repurposing Compound Library | Saccharide and Glycoside Natural Product Library | Microbial Natural Product Library | Inhibitor Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |
United States
